P.J. Mease, MD, MACR, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA;
K. Winthrop MD, MPH, Oregon Health Sciences University, School of Public Health, Portland, Oregon, USA.
J Rheumatol. 2022 Jun;49(6 Suppl 1):10-12. doi: 10.3899/jrheum.211319. Epub 2022 Mar 1.
The efficacy and safety of coronavirus disease 2019 (COVID-19) vaccination in patients with autoimmune inflammatory diseases (AIRDs) who are treated with immunomodulatory therapies was the focus of a symposium at the 2021 virtual annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). The keynote address was delivered by Dr. Jeffrey Curtis, chair of the American College of Rheumatology COVID-19 Vaccine Clinical Guidance task force, detailing what we do and do not know about vaccine efficacy and safety in patients with AIRDs and providing guidance about the need for modification of dosing in some immunomodulatory medications for optimal vaccine response. A consensus of the task force was that all patients with AIRDs should be vaccinated as soon as it is allowed in their respective locations, since the benefits of increased protection against COVID-19 infection outweigh the potential for vaccination reactions, including flares of underlying disease, or for reduced efficacy of vaccination because of disease state or medications. Key issues among patient research partners with psoriatic disease expressed in the premeeting survey and panel discussion/question-and-answer period included: vaccine efficacy and safety, the need to continue safe social habits and masking, how to assess efficacy of vaccination, how to deal with vaccine hesitancy among social contacts, medication management relative to vaccination, and concerns about the adequacy of ongoing telehealth visits vs the convenience of that technology.
2021 年美国风湿病学会（ACR）年会虚拟会议期间，一项关于接受免疫调节治疗的自身免疫性炎症性疾病（AIRD）患者接种 2019 冠状病毒病（COVID-19）疫苗的疗效和安全性的研讨会成为焦点。皮肤病学研究和评估协会（GRAPPA）的专题讨论会的主旨演讲由美国风湿病学会 COVID-19 疫苗临床指导工作组主席 Jeffrey Curtis 博士发表，详细介绍了我们对 AIRD 患者疫苗疗效和安全性的了解和未知，并就一些免疫调节药物的剂量调整提供了指导意见，以获得最佳的疫苗反应。工作组的共识是，只要 AIRD 患者在其所在地区允许接种疫苗，就应尽快接种，因为增加 COVID-19 感染防护的益处大于潜在的疫苗反应，包括潜在疾病的发作，或因疾病状态或药物而降低疫苗的疗效。在会前调查和小组讨论/问答环节中，银屑病患者的患者研究合作伙伴表达的关键问题包括：疫苗的疗效和安全性、继续安全社交习惯和戴口罩的必要性、如何评估疫苗的效果、如何处理社交接触者的疫苗犹豫问题、与疫苗接种相关的药物管理以及对持续远程医疗访问的充分性与该技术便利性的担忧。
